Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Operating Leases (2019 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Operating Leases for 6 consecutive years, with $53.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 4.73% year-over-year to $53.8 million, compared with a TTM value of $53.8 million through Dec 2025, down 4.73%, and an annual FY2025 reading of $54.8 million, up 1.51% over the prior year.
  • Operating Leases was $53.8 million for Q4 2025 at Enanta Pharmaceuticals, down from $54.8 million in the prior quarter.
  • Across five years, Operating Leases topped out at $56.5 million in Q1 2025 and bottomed at $1.1 million in Q3 2021.
  • Average Operating Leases over 5 years is $30.6 million, with a median of $22.4 million recorded in 2022.
  • The sharpest move saw Operating Leases crashed 70.66% in 2021, then soared 1886.86% in 2022.
  • Year by year, Operating Leases stood at $16.0 million in 2021, then surged by 36.98% to $21.9 million in 2022, then fell by 6.11% to $20.5 million in 2023, then surged by 175.06% to $56.5 million in 2024, then fell by 4.73% to $53.8 million in 2025.
  • Business Quant data shows Operating Leases for ENTA at $53.8 million in Q4 2025, $54.8 million in Q3 2025, and $55.7 million in Q2 2025.